US Medicare Patients now have access to CBD products via a federal pilot program, which has helped boost the cannabis stock.
Many investors have interpreted the inclusion of CBD in formal medical care for the first-time as an indication that the drug is legitimate. However, at this time, the program remains limited.
The US Food and Drug Administration published a memo last week that confirmed it would not enforce rules which normally limit CBD products as long as these are used in the programmes and they meet certain conditions.
The policy works alongside a Centers for Medicare & Medicaid Services (CMS) initiative that allows healthcare providers in selected programmes, including ACO REACH and the Enhancing Oncology Model, to give patients up to $500 worth of CBD products per year. The products are provided to the patients directly during their care rather than forcing them to buy CBD.
The limited scheme has seen many producers compete to get their product included. Further expansions are set to take place in the next few months.
boc_stock symbol=”MSOS”
The landmark is limited, however.
The memo is titled “In its Memo” Hemp-derived Cannabidiol Products as Medical Research ModelsThe FDA says it doesn’t intend to enforce Sections 502(f),(1) and 505 (of the Federal Food, Drug, and Cosmetic Act) for hemp-derived CBD product that are provided to Medicare beneficiaries as part of Title XVIII Programmes.
This policy is applicable to all orally administered drugs prescribed by a physician as part of an overall course of treatment.
The Executive Order, 14370 signed by the President in December 2025 directed all federal agencies to explore and expand their research on cannabis-derived products.
Medicare does not cover the costs. The providers are responsible for paying the costs of these products and it is not up to patients to make claims. It means, in practice, that CBD may be provided at no charge to some patients, but is not covered under Medicare.
Moreover, certain products are only allowed. The products must come from hemp, be within federal THC limitations, and not be inhaled. These rules aim to maintain tight control of the program while still allowing providers and researchers to experiment with CBD’s potential use in health care.
US regulators have been working to develop broader CBD rules. The FDA sent a policy draft on CBD regulation in March to the White House, for the Office of Information and Regulatory Affairs’ review. However, full details are not yet available.
In November 2026 new federal hemp rules will be in effect, which tighten the limits of THC. This could result in a reduction of the CBD products eligible under federal law. It may also affect the program.
READ MORE…
The Commercial Market is Growing, but Legal Issues Are Emerging
A notable response has been seen in the market as a result of this policy change. Cannabis equities posted their highest weekly performance since months after investors took notice of signs that CBD has begun to make its way into regulated health channels.
After the announcements came out, AdvisorShares Pure US Cannabis ETF – which tracks US cannabis leaders – rose rapidly, reflecting renewed confidence around federal reform.
Early signs of positioning in the commercial arena are also emerging. Cornbread Hemp announced that it had secured an exclusive agreement to supply Alliant Purchasing. This group buying organisation has a network of tens and thousands of locations who participate in CMS-linked model.
The agreement will allow the distribution of its products through approved healthcare purchasing channels.
The rollout of the CMS initiative is being scrutinized by law enforcement despite this positive development. Smart Approaches to Marijuana along with other organizations have challenged the CMS initiative. The lawsuit argues that this exceeded the authority of the CMS and it was implemented in a way which did not follow proper rulemaking processes.
The federal court has rejected an initial request for a halt to the program, but will hear arguments about a preliminary order later in this month.
In this context, long-term expectations for the program are still uncertain. Success will be determined by the uptake of CBD in CMS models as well as how federal regulators address broader CBD policy questions.
The regulatory landscape could change dramatically within months, with new hemp regulations set to come into effect in November of 2026. These rules will tighten THC limitations and possibly narrow the product range that is eligible. A full guide on CBD product regulation has not yet been published by the US Food and Drug Administration, and this leaves important compliance issues unresolved.
US Medicare patients now have the option to purchase cannabidiol products, thanks to a groundbreaking federal pilot project. This has helped increase cannabis stocks.
For now, CBD is only available in formal healthcare settings. While this has been hailed by many as medical legitimacy, it remains a limited scheme.
The US Food and Drug Administration published a memo last week that confirmed it would not enforce rules which normally limit CBD products as long as these are used in the programmes and they meet certain conditions.
The policy works alongside a Centers for Medicare & Medicaid Services (CMS) initiative that allows healthcare providers in selected programmes, including ACO REACH and the Enhancing Oncology Model, to give patients up to $500 worth of CBD products per year. The products are provided to the patients directly during their care rather than forcing them to buy CBD.
The limited scheme has seen many producers compete to get their product included. Further expansions are set to take place in the next few months.
boc_stock symbol=”MSOS”
The landmark is limited, however.
The memo is titled “In its Memo” Hemp-derived Cannabidiol Products as Medical Research ModelsThe FDA has stated that it will not enforce the sections 502 (f) (1) and 505 of Federal Food, Drug, and Cosmetic Act when providing CBD-derived hemp products to Medicare recipients under Title XVIII programs.
Orally administered medications are covered by the policy if they’re prescribed under a doctor’s direction and part of broader care.
The Executive Order, 14370 signed by the President in December 2025 directed all federal agencies to explore and expand their research on cannabis-derived products.
Medicare does not cover the costs. The providers are responsible for paying the costs of these products and it is not up to patients to make claims. It means, in practice, that CBD may be provided at no charge to some patients, but isn’t included as part of Medicare standard coverage.
Moreover, certain products are only allowed. The products must come from hemp, be within federal THC limitations, and not be inhaled. They are intended to control the programme while also allowing healthcare providers to explore how CBD could be used.
US regulators are still working on more comprehensive rules regarding CBD. The FDA sent a policy draft on CBD regulation in March to the White House, for the Office of Information and Regulatory Affairs’ review. However, full details are not yet available.
New federal hemp regulations will come into effect on November 20, 2026. These rules tighten THC limits. This could result in a reduction of the CBD products eligible under federal law. It may also affect the program.
READ MORE…
The Commercial Market is Growing, but Legal Issues Are Emerging
Markets have already responded in a significant way to the policy change. Cannabis shares recorded the best performance week in several months after investors took note of signs that CBD has begun to make its way into regulated healthcare channels.
After the announcements came out, AdvisorShares Pure US Cannabis ETF was up sharply, which tracked leading US cannabis companies. This reflected renewed optimism regarding federal reform.
Early signs of positioning in the commercial arena are also emerging. Cornbread Hemp has announced an exclusive agreement to supply Alliant Purchasing. The group purchasing organization’s network includes tens thousands of providers participating in CMS-linked model.
The agreement will allow the distribution of its products through approved healthcare purchasing channels.
The rollout of the CMS initiative is being scrutinized by law enforcement despite this positive development. Smart Approaches to Marijuana along with other organizations have challenged the CMS initiative. The lawsuit argues that this exceeded the authority of the CMS and it was implemented in a way which did not follow proper rulemaking processes.
The federal court has rejected an initial request for a halt to the program, but will hear arguments about a preliminary order later in this month.
The long-term prospects of the program remain uncertain. Success will be determined by the uptake of CBD in CMS models as well as how federal regulators address broader CBD policy questions.
The regulatory landscape could change dramatically within months, with new hemp regulations set to come into effect in November of 2026. These rules will tighten THC limitations and possibly narrow the product range that is eligible. At the same, the US Food and Drug Administration still hasn’t published full guidelines on how CBD will be regulated. This leaves important compliance issues unresolved.
Cannabis Law Resources for Poland
Browse essential legal pages on cannabis sales and cultivation in Poland. These guides will help you understand the legal requirements, such as certification, licensing, and other compliance issues.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland